Statistics for Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study
Total visits
| views | |
|---|---|
| Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study | 89 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| Paradigm-poster.pdf(legacy) | 110 |
| Paradigm-poster.pdf | 5 |
Top country views
| views | |
|---|---|
| United States | 39 |
| China | 22 |
| Portugal | 12 |
| Canada | 6 |
| Netherlands | 3 |
| Ukraine | 3 |
| Brazil | 1 |
| India | 1 |
| Latvia | 1 |
| Russia | 1 |
| Taiwan | 1 |
Top city views
| views | |
|---|---|
| Delhi | 1 |